Adjunto un artículo de mayo de 2016. Nada que no sepamos ya ( gracias Leyla). Seguimos leyendo
. Si ya hay otro hilo sobre el Rituximab cambiarlo sin problemas, en un vistazo rápido yo no le he encontradoUn abrazo.
Extended B cell phenotype in patients with myalgic encephalomyelitis/chronic fatigue syndrome: a cross-sectional study
Por:Mensah, F (Mensah, F.)[ 1 ] ; Bansal, A (Bansal, A.)[ 2 ] ; Berkovitz, S (Berkovitz, S.)[ 3 ] ; Sharma, A (Sharma, A.)[ 1 ] ; Reddy, V (Reddy, V.)[ 1 ] ; Leandro, MJ (Leandro, M. J.)[ 1 ] ; Cambridge, G (Cambridge, G.)[ 1 ]
CLINICAL AND EXPERIMENTAL IMMUNOLOGY
Volumen: 184 Número: 2 Páginas: 237-247
DOI: 10.1111/cei.12749
Fecha de publicación: MAY 2016
Resumen
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a heterogeneous condition of unknown aetiology characterized by multiple symptoms including fatigue, post-exertional malaise and cognitive impairment, lasting for at least 6 months. Recently, two clinical trials of B cell depletion therapy with rituximab (anti-CD20) reported convincing improvement in symptoms. A possible but undefined role for B cells has therefore been proposed. Studies of the relative percentages of B cell subsets in patients with ME/CFS have not revealed any reproducible differences from healthy controls (HC). In order to explore whether more subtle alterations in B cell subsets related to B cell differentiation exist in ME/CFS patients we used flow cytometry to immunophenotype CD19(+) B cells. The panel utilized immunoglobulin (Ig)D, CD27 and CD38 (classical B cell subsets) together with additional markers. A total of 38 patients fulfilling Canadian, Centre for Disease Control and Fukuda ME/CFS criteria and 32 age- and sex-matched HC were included. We found no difference in percentages of classical subsets between ME/CFS patients and HC. However, we observed an increase in frequency (P<001) and expression (MFI; P=003) of CD24 on total B cells, confined to IgD(+) subsets. Within memory subsets, a higher frequency of CD21(+)CD38(-) B cells (>20%) was associated with the presence of ME/CFS [odds ratio: 347 (115-1046); P=003] compared with HC, and there was a negative correlation with disease duration. In conclusion, we identified possible changes in B cell phenotype in patients with ME/CFS. These may reflect altered B cell function and, if confirmed in other patient cohorts, could provide a platform for studies based on clinical course or responsiveness to rituximab therapy.
Palabras clave
Palabras clave de autor:B cells; chronic fatigue syndrome; flow cytometry; human; myalgic encephalomyelitis
KeyWords Plus:SYSTEMIC-LUPUS-ERYTHEMATOSUS; CD24 GENE POLYMORPHISMS; IMMUNOLOGICAL ABNORMALITIES; RHEUMATOID-ARTHRITIS; MITOCHONDRIAL DYSFUNCTION; AUTOIMMUNE-DISEASES; MULTIPLE-SCLEROSIS; IMMUNE-RESPONSE; SYNDROME ME/CFS; IGG SUBCLASSES